3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
77
pembrolizumab
65
Carboplatin
57
Bevacizumab
57
Specimen Handling
49
Magnetic Resonance Spectroscopy
40
Cisplatin
35
olaparib
31
Gemcitabine
27
liposomal doxorubicin
25
Biopsy
22
Taxes
19
Cyclophosphamide
18
Topotecan
17
Nivolumab
17
Doxorubicin
16
Immunoglobulin G
15
niraparib
14
Letrozole
14
Disulfides
14
lenvatinib
13
fludarabine
13
Surveys and Questionnaires
12
Drug Therapy
12
Radiotherapy
11
Platinum
11
atezolizumab
10
abemaciclib
10
durvalumab
9
Fulvestrant
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Gynecologic
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled
NCT05920798
2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2
Recruiting
40 enrolled